Document:

Exhibit 10.55

 

March 16, 2018

 

Michael Poirier

Qualigen, Inc.

2042 Corte Del Nogal

Carlsbad, CA 92009

 

	 	Re:	LICENSE OF FASTPACK 2.0

 

Dear Michael:

 

Sekisui Diagnostics, LLC
(“Sekisui”) is pleased to present to Qualigen, Inc. this Letter of Intent (“LOI”) setting forth certain
business terms relating to a potential worldwide license between Qualigen as Licensor and Sekisui as Licensee relating to a certain
point of care, rapid quantitative immunoassay analyzer, as well as all associated intellectual property and technology, including,
but not limited to, any assays, plasma separation devices, dispensers, and pouches related thereto (collectively known as the “FastPack
2.0 System”) currently under development by Qualigen. Qualigen and Sekisui are sometimes individually herein referred to
as a “Party” and collectively as the “Parties.”

 

The portions of this LOI
which are specified herein to be non-binding shall be non-binding, and the portions of this LOI which are specified herein to be
binding shall be binding. Specifically, this LOI is not intended to be and will not create any legal binding obligation on the
Parties, except as specifically set out in Part B below. In particular, and for avoidance of doubt: the concurrence in this
LOI, and/or during the Negotiating Term, upon material terms for the “License Agreement” (as defined below) does not
create a binding license agreement or other contractually binding agreement between the Parties as to such material terms; there
shall be no binding license agreement unless and until the Parties execute and deliver a definitive License Agreement negotiated
following execution of this LOI. Qualigen expressly acknowledges that any proposed License Agreement must be approved by necessary
levels of Sekisui corporate authority before it is executed and delivered by Sekisui. It is further mutually acknowledged that
the License Agreement would need to contain additional terms and conditions which are appropriate for transactions of this type,
including, but not limited to, representations, warranties, and covenants concerning title to the intellectual property, authority
to execute and perform the License Agreement, no infringement, and other customary provisions.

 

Recitals

 

WHEREAS, Qualigen is the
owner of all right, title and interest in and to the “FastPack 2.0 System” including all intellectual property, including
all of Qualigen’s patent rights (“Patent Rights”) and know-how (“Know-How”) related thereto as more
fully described herein; and

 

WHEREAS, Qualigen and Sekisui
are parties to that certain Distribution and Development Agreement dated as of May 1, 2016, as amended (the “Distribution
Agreement”); and

 

    	 

    	Michael Poirier
Page 2
	 

    

 

WHEREAS, Sekisui anticipates
that its sales of Qualigen FastPack IP System instruments and Qualigen FastPack IP System and FastPack “1.0” System
reagent test kits pursuant to the Distribution Agreement may increase in the future, subject to the release of the 2.0 System and
changes to the competitive landscape; and

 

WHEREAS, pursuant to the
Distribution Agreement Sekisui has heretofore provided substantial sums of monies to Qualigen to help fund the development of the
FastPack 2.0 System, with a view to obtaining all necessary regulatory approvals to permit the marketing and commercialization
of the FastPack 2.0 System in the United States and worldwide; and

 

WHEREAS, the development
and manufacture of the FastPack 2.0 System has been subject to material delays; and

 

WHEREAS, Sekisui has determined
that the costs of development of the FastPack 2.0 System have substantially escalated, and the future research and development
costs are currently projected by Sekisui to cost in excess of five million dollars ($5,000,000); and

 

WHEREAS, Qualigen does
not possess the resources to continue the development of the FastPack 2.0 System without Sekisui financial assistance; and

 

WHEREAS, Sekisui desires
to negotiate and enter into a definitive license agreement with Qualigen granting to Sekisui an exclusive worldwide assignable
license to use, manufacture, develop, make, sell, distribute, export and import the FastPack 2.0 System on the material terms hereinafter
described (the “License Agreement”); and

 

WHEREAS, Qualigen desires
to negotiate and enter into the License Agreement; and

 

WHEREAS, Qualigen needs
to assure, regularize and rationalize its cash inflows and outflows, in order to maintain a stable and secure financial position;
and

 

WHEREAS, Sekisui is willing
to provide to Qualigen a $500,000 lump-sum cash payment for research and development (the “ R&D Payment”), which
R&D Payment will be repaid in full to Sekisui as set forth in this LOI if the Parties are unable to arrive at a binding License
Agreement on or prior to the expiration of the Negotiating Term (as hereinafter defined).

 

Part A – Non-Binding Business Terms

 

	 	(1)	For the period of ninety (90) days from the date hereof (the “Negotiating Term”), Qualigen and Sekisui shall in good faith promptly proceed to negotiate a definitive License Agreement containing among other things, the material terms substantially in accordance with this LOI. This LOI shall terminate if a definitive License Agreement mutually satisfactory to the Parties has not been entered into by 6:01 pm (California time) on the day that is ninety days after the execution date hereof, as such time and date may be extended by the Parties by a writing signed by each of the Parties.

 

    	 

    	Michael Poirier
Page 3
	 

    

 

	 	(2)	The Parties contemplate the definitive License Agreement would include the following material terms:

 

(a) The License
Agreement shall provide that Qualigen shall grant to Sekisui and its affiliates:

 

(i) an exclusive
(including with respect to Qualigen), all-fields, worldwide, assignable license, including the rights to sublicense through multiple
tiers of sublicense, under all Qualigen FastPack 2.0 Patent Rights and Qualigen Know-How (except for Qualigen intellectual property
that pertains to FastPack “1.0”/IP as well as to the FastPack 2.0 System). Qualigen FastPack 2.0 Patent Rights include
without limitation the patents and pending patent applications listed in Schedule A and any patent or patent application claiming
priority thereto; and

 

(ii) an exclusive
(including with respect to Qualigen), worldwide, assignable license, including the rights to sublicense through multiple tiers
of sublicense, under all Qualigen Patent Rights and Qualigen Know-How not included in the license grant described in Section A2(a)(i)
above, limited to the field of use consisting of developing, making, having made, using, manufacturing, offering for sale, selling,
having sold, exporting and importing all products (“Licensed Products”) related to the FastPack 2.0 System and future
developments/ improvements/ enhancements thereof (i.e., FastPack 2.1, FastPack 3.0, etc.). Qualigen Patent Rights include all patents
and pending patent applications, and any patents and patent applications claiming priority thereto, owned in whole or in part by
Qualigen, necessary or appropriate for the aforesaid field of use, including without limitation point of care, quantitative immunoassay
analyzers, including, but not limited to, any assays, reagents, plasma separation devices, dispensers, and pouches related thereto,
and all methods, processes, systems, and kits related thereto.

 

(b) The term
of the License Agreement (“Term”) shall be as agreed to in the License Agreement, but at a minimum shall (subject to
Section 2(g) below) remain in effect until the expiration of the last to expire patent issued with respect to Qualigen’s
Patent Rights or such shorter period as Sekisui may determine during the Negotiation Period.

 

(c) The License
Agreement shall provide that all further research/development of, clinical trials of and other seeking of regulatory approval for
Licensed Products shall be performed by Sekisui (or by Sekisui contractors other than Qualigen). Simultaneously with the signing
of the License Agreement, the Distribution Agreement shall be amended to terminate any further research/development of, clinical
trials of and other seeking of regulatory approval for Licensed Products by Qualigen. Qualigen shall fully cooperate in the transition
of such responsibilities to Sekisui, including by (i) technology transfer of all Qualigen documentation, designs, plans, bills
of materials, etc., as well as of other Qualigen trade secrets, (ii) delivering (at Sekisui’s expense) all physical FastPack
2.0 System-specific items as instructed by Sekisui, and (iii) signing all necessary filings, or allowing same to be filed, as necessary,
in Qualigen’s name. It is understood that such cooperation obligation shall not be construed to require Qualigen to incur
any material cost. During the Negotiation Period, the parties will also discuss which Qualigen employees, if any, Sekisui may wish
to hire, and an arrangement for providing upon Sekisui request the services (billed at Qualigen’s standard hourly rates)
of certain Qualigen employees.

 

    	 

    	Michael Poirier
Page 4
	 

    

 

(d) The License
Agreement shall provide that all manufacturing of Licensed Products shall be performed for the benefit and at the cost of Sekisui
by a (non-Qualigen) manufacturer or manufacturers selected by Sekisui, including without limitation, any affiliate of Sekisui,
on such terms as Sekisui in its sole discretion shall determine, and that Sekisui shall not use any Qualigen marks for the Licensed
Products except for any products currently containing any of Qualigen’s marks.

 

(e) During the
Term of the License Agreement, Sekisui shall pay Qualigen on a quarterly basis a 3.25% royalty on “Net Sales” (as defined
with a customary meaning in the License Agreement) of Licensed Products the manufacture, sale or use of which is covered by valid
unexpired Qualigen Patent Rights claims and a 1.75% royalty on Net Sales of Licensed Products the manufacture, sale and use of
which are covered only by Qualigen Know-How (e.g., the last applicable Qualigen Patent Rights claim has expired or the Net Sales
are in a country where no applicable Qualigen Patent Rights claim has yet been granted).

 

(f) Simultaneously
with the signing of the License Agreement, the Distribution Agreement shall be amended to provide that should Sekisui subsequently
acquire in a voluntary transaction substantially all of the assets or of the capital stock of Qualigen (by merger or otherwise)
there shall be credited against the purchase price of such acquisition, any unrepaid amounts of the R&D Payment and any Financing
Payments amounts (as defined in the Distribution Agreement) paid to Qualigen per the Distribution Agreement.

 

(g) Sekisui shall
use its commercially reasonable efforts to, subject only to “force majeure” delays, within two (2) years of the execution
date of the License Agreement file at least one 510-K application with the FDA for the FastPack 2.0 System with respect to reagents
for Vitamin D immunoassays or reagents for assays for any other target. Subject only to force majeure delays, if Sekisui fails
to file any 510-K application for the FastPack 2.0 System with the FDA with respect to reagents for Vitamin D immunoassays or reagents
for assays for any other target within two years of the execution date of the License Agreement, (i) the License Agreement shall
automatically terminate, (ii) Qualigen shall have the right to purchase from Sekisui at a fair market value price certain specific
physical items exclusively used as part of the FastPack 2.0 System-as agreed between Qualigen and Sekisui, and (iii) Qualigen shall
forthwith reimburse and repay the R&D Payment in full to Sekisui in or within six (6) months from the date of termination of
the License Agreement. Following the termination of the License Agreement, Sekisui agrees to negotiate in good faith a grant to
Qualigen of a non-exclusive worldwide license under certain of Sekisui’s Patent Rights developed exclusively as part of the
FastPack 2.0 System that were made during the term of the License Agreement, limited to the field of use consisting of developing,
making, having made, using, manufacturing, offering for sale, selling, having sold, exporting and importing Licensed Products,
including the length of the license term thereof and royalties payable in respect thereto.

 

    	 

    	Michael Poirier
Page 5
	 

    

 

(h) During the
Term of the License Agreement, Qualigen at its expense, shall be responsible for preparing, filing, and maintaining all patent
applications and patents included (as of the date of the License Agreement) in the Qualigen Patent Rights in the jurisdictions
in which Qualigen Patent Rights have heretofore been filed, and shall consult with and provide copies thereof to Sekisui. During
the Term, Qualigen will not allow any of the Qualigen Patent Rights to expire early, go abandoned, or otherwise allow the loss
of rights in any such jurisdiction (but not including claim limitation, etc., as recommended by Qualigen patent counsel). Qualigen
will notify Sekisui a minimum of 60 days prior to the loss of any rights and Sekisui will have the option, at its sole discretion,
to prevent the loss of rights. During the Term, Sekisui shall have the option, at its expense, to prepare, file, prosecute, and
maintain Qualigen Patent Rights in one or more additional jurisdictions. Sekisui shall have the option, at its expense, to prepare,
file, prosecute, and maintain Sekisui Patent Rights in any jurisdiction(s).

 

(i) All rights
and licenses granted under or pursuant to the License Agreement by Qualigen are, and will otherwise be deemed, for all purposes
of Section 365(n) of the U.S. Bankruptcy Code, license of rights to “intellectual property” as defined in Section 101
of the U.S. Bankruptcy Code.

 

(j) Simultaneously
with the signing of the License Agreement, the Distribution Agreement shall be amended to provide that for each calendar quarter
through March 2020, Sekisui shall make purchases and/or royalty payments in a minimum aggregate amount of $900,000 per calendar
quarter (the “Minimum Amount”). At the end of each calendar quarter, if there is a shortfall in the Minimum Amount
for such quarter, Sekisui shall pay the entire shortfall amount to Qualigen on the last day of such quarter and shall then have
the right to credit such shortfall payment against future purchases of Qualigen goods. (However, payments by way of such a credit
shall not count toward the Minimum Amount for any quarter other than the quarter in which such initial shortfall occurred.) The
Minimum Amount shall include without limitation all purchases for instruments, reagents, test kits, etc. and shall include the
aggregate amount of any royalty payments made to Qualigen during any such quarter. (For avoidance of doubt: there are no minimum
purchase requirements after March 2020.) If anyone sells or distributes a competitive product in a market where Sekisui is selling
or distributing the Fastpack systems, upon written notice from Sekisui to Qualigen, the parties agree to negotiate in good faith
a reduction in the Minimum Amount. Except as set forth in this subsection (j), purchases will continue to be made in accordance
with the Distribution Agreement.

 

(k) The existing
letter agreement between Sekisui and Qualigen regarding discretionary prepayments of certain instrument purchase orders by Sekisui
shall remain in effect.

 

    	 

    	Michael Poirier
Page 6
	 

    

 

(l) Simultaneously
with the signing of the License Agreement, the Distribution Agreement shall be amended to expressly exclude from the Section 1.23
definition of “Sale Transaction” (i) any “reverse merger” limited to merging with a “shell public
corporation” (or a transitory merger subsidiary thereof) as long as (a) the existing holders of Qualigen equity securities
as of before such transaction hold, by virtue of such transaction, at least 80% of the equity securities of the surviving or parent
entity, (b) Qualigen provides a detailed description to Sekisui of the proposed transaction and such proposal is satisfactory to
Sekiusui in its sole discretion, and (c) such transaction does not adversely impact Sekisui’s rights under the Distribution
Agreement (including, without limitation, the surviving or parent entity agreeing in writing for the benefit of Sekisui that until
the expiration or termination of the Distribution Agreement Sekisui’s rights under Section 9.3 and 9.4 of the Distribution
Agreement shall continue to apply to Qualigen and also (mutatis mutandis) apply to any such Sale Transaction involving such surviving
or parent entity rather than formally involving Qualigen itself), (ii) any sale or license of any rights to the “therapeutics
patents” and/or the program to develop them and (iii) any license of rights for the licensee’s manufacture and sale
of one or more Qualigen products (but only if such license is limited to manufacture and sale of such product(s) in and for one
or more specified country(ies) where Sekisui determines it is not interested in pursuing the market).

 

Part B – Binding Terms

 

The provisions of this Part B shall be legally
binding upon both Parties immediately upon their joint execution of this LOI, and shall survive the termination or expiration of
this LOI.

 

(3) During the Negotiating
Term, as the same may be extended, Qualigen shall provide and make available to Sekisui (under NDA) copies of all Qualigen’s
Patent Rights, Qualigen’s Know-How, as well as all records, plans, designs, communications, regulatory filings and all other
writings or information relating to the FastPack 2.0 System, Qualigen’s Patent Rights and Qualigen’s Know-How, as well
as all results or reports of any clinical trials or filings or communications with the FDA involving the FastPack 2.0 System. Upon
reasonable advance notice, Qualigen shall also make available to Sekisui, or its representatives, access to its employees and/
or contractors who have participated in or who have knowledge concerning the FastPack 2.0 System.

 

(4) Sekisui shall upon
joint execution of this LOI provide to Qualigen a $500,000 lump-sum cash R&D Payment (the “R&D Payment”). If
for any reason the Parties are unable or unwilling to execute and deliver a binding License Agreement by the expiration or termination
of the Negotiating Term, Qualigen shall repay the R&D Payment in full to Sekisui in or within one hundred and eighty (180)
days after the expiration or termination of the Negotiation Term. Notwithstanding anything to the contrary herein contained, if
Sekisui shall at any time during the Negotiating Term determine not to proceed with the negotiation or execution of a definitive
License Agreement, it shall notify Qualigen in writing of its determination and the Negotiating Term shall thereupon terminate
immediately upon such written notification. If the R&D Payment is not repaid when due, interest shall thereafter accrue at
the rate of twelve (12%) percent per annum on the amount of the R&D Payment remaining unpaid until all sums are paid in full,
and in addition Sekisui shall be entitled to all costs and expenses (including reasonable attorney’s fees) incurred in connection
with the enforcement and repayment and/or collection of said R&D Payment. Additionally, simultaneously with the execution and
delivery of this LOI, Qualigen shall execute and deliver to Sekisui, a Security Agreement in form and substance acceptable to Sekisui,
granting to Sekisui a security interest in all of Qualigen’s assets to secure the repayment in full of the R&D Payment
in accordance with the terms of this Section B (4) of the LOI, which security agreement shall survive the termination or expiration
of this LOI. Such security agreement shall provide that the priority of such security interest will be subordinated to the security
interest of Qualigen’s existing working capital revolving line of credit and any future working capital revolving line of
credit that replaces in its entirety Qualigen’s existing working capital revolving line of credit.

 

    	 

    	Michael Poirier
Page 7
	 

    

 

(5) During the Negotiating
Term, and until a License Agreement is mutually executed and delivered by the Parties, Qualigen shall continue to perform all its
obligations as set forth in the Distribution Agreement.

 

(6) Whether or not a License
Agreement is executed, Qualigen and Sekisui shall each be solely responsible for and bear their own respective costs and expenses
(including, without limitation, expenses of legal counsel, accountants, other representatives and advisors) of pursuing or consummating
a License Agreement and the transactions contemplated thereby.

 

(7) Except as may be required
by law, neither Sekisui nor Qualigen shall make any public statement with respect to the existence of this LOI or the transactions
contemplated hereby without the consent of the other. If any public statement is required by law, the Party required to make such
statement will consult with the other Party in connection therewith but such consultation shall not prevent a Party from meeting
such legal obligations.

 

(8) Qualigen’s repayment
to Sekisui of the McKesson 2016 marketing fee of $190,000 previously paid directly to McKesson by Sekisui on behalf of Qualigen
shall be paid as soon as reasonably practicable, but in all events on or before September 1, 2018.

 

(9) Except as, if and when
specifically modified by the terms of the License Agreement or an amendment of the Distribution Agreement entered into simultaneously
with the signing of the License Agreement, the Distribution Agreement does and shall remain in full force and effect.

 

(10) The terms of this
LOI shall be governed by and construed in accordance with the laws of Delaware, without regard to principles of conflict of laws.

 

(11) This LOI cannot be
amended or waived except in an express writing signed by both Parties.

 

Please sign this Letter of Intent in the space
indicated below to confirm our mutual understanding as set forth herein and return a signed copy to the undersigned. This Letter
of Intent may be signed in counterparts.

 

	 	Very truly yours,
	 	 	 
	 	Sekisui Diagnostics, LLC
	 	 	 
	 	By:	/s/
    Robert T. Schruender

 

	ACCEPTED AND AGREED:	 
	 	 	 
	Qualigen, Inc.	 
	 	 	 
	By:	/s/
    Michael PoirierExhibit
10.56

 

Amendment
to Distribution and Development Agreement

 

This
Amendment to Distribution and Development Agreement (this “Amendment”) is entered into by and between
Sekisui Diagnostics, LLC, a Delaware limited liability company (“Sekisui”),
and Qualigen, Inc., a Delaware corporation (“Qualigen”),
and shall be effective as of April 2, 2018. This Amendment amends that certain Distribution and Development Agreement dated May
1, 2016 between Sekisui and Qualigen, as amended to the date hereof (collectively, the “Distribution and Development
Agreement”).

 

1.
Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms
in the Distribution and Development Agreement.

 

2.
Amendment.

 

2.1
Section 1.18 of the Distribution and Development Agreement is hereby amended by striking such section in its entirety and
substituting the following Section 1.18 in place thereof: “Products shall mean all of Qualigen’s current and future
products, including those listed in Exhibit D, for sale under the trade names listed with such products, including any improvements
thereto, but expressly excluding therefrom any product exclusively used in the fields of therapeutics and/or prophylactics (rather
than in the field of diagnostics), (b) any program to develop one or more of such therapeutics and/or prophylactics products and
(c) any products based upon one or more of such therapeutics and/or prophylactics inventions, but only to the extent of its use
in the fields of therapeutics and/or prophylactics.

 

3.
No Other Amendment. Except as expressly provided in this Amendment, the Distribution and Development Agreement is, and shall
continue to be, in full force and effect in accordance with its terms, without further amendment thereto.

 

4.
Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed an original document, and all
of which, together, shall be deemed one instrument. PDF copies or photocopies of signatures, and delivery by email of PDF copies,
shall be as effective as originals.

 

In
Witness Whereof, the parties to this Amendment
to Distribution and Development Agreement, having read and understood the foregoing, acknowledge their legally binding acceptance
of this Amendment to Distribution and Development Agreement by the signatures of their respective authorized representatives below.

 

	Sekisui
    Diagnostics, LLC	 	Qualigen,
    Inc,
	 	 	 
	By:	/s/
    Robert T. Schruender	 	By:	/s/
    Michael Poirier
	Name:	Robert
    T. Schruender	 	Name:	Michael
    Poirier
	Title:	President
    and CEO	 	Title:	President
    and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]